Theravance Biopharma, Inc. (TBPH)
17.01
0.00 (0.00%)
USD |
NASDAQ |
Aug 24, 16:00
16.98
-0.03
(-0.18%)
Pre-Market: 09:21
Theravance Biopharma Enterprise Value : 566.37M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 566.37M |
| August 21, 2026 | 566.37M |
| August 20, 2026 | 563.26M |
| August 19, 2026 | 565.34M |
| August 18, 2026 | 563.26M |
| August 17, 2026 | 561.70M |
| August 14, 2026 | 564.30M |
| August 13, 2026 | 561.70M |
| August 12, 2026 | 561.70M |
| August 11, 2026 | 561.70M |
| August 10, 2026 | 561.18M |
| August 07, 2026 | 562.22M |
| August 06, 2026 | 561.70M |
| August 05, 2026 | 560.66M |
| August 04, 2026 | 559.63M |
| August 03, 2026 | 559.11M |
| July 31, 2026 | 558.59M |
| July 30, 2026 | 558.07M |
| July 29, 2026 | 558.07M |
| July 28, 2026 | 560.15M |
| July 27, 2026 | 558.59M |
| July 24, 2026 | 558.59M |
| July 23, 2026 | 558.59M |
| July 22, 2026 | 555.99M |
| July 21, 2026 | 557.55M |
| Date | Value |
|---|---|
| July 20, 2026 | 555.99M |
| July 17, 2026 | 562.22M |
| July 16, 2026 | 564.30M |
| July 15, 2026 | 562.22M |
| July 14, 2026 | 561.70M |
| July 13, 2026 | 560.66M |
| July 10, 2026 | 562.22M |
| July 09, 2026 | 564.82M |
| July 08, 2026 | 565.85M |
| July 07, 2026 | 566.37M |
| July 06, 2026 | 565.85M |
| July 02, 2026 | 562.22M |
| July 01, 2026 | 564.82M |
| June 30, 2026 | 565.85M |
| June 29, 2026 | 557.48M |
| June 26, 2026 | 586.84M |
| June 25, 2026 | 574.48M |
| June 24, 2026 | 568.30M |
| June 23, 2026 | 552.84M |
| June 22, 2026 | 531.72M |
| June 18, 2026 | 532.75M |
| June 17, 2026 | 539.45M |
| June 16, 2026 | 538.42M |
| June 15, 2026 | 519.36M |
| June 12, 2026 | 535.84M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Zymeworks, Inc. | 2.068B |
| Viatris, Inc. | 31.32B |
| Ocular Therapeutix, Inc. | 1.848B |
| ANI Pharmaceuticals, Inc. | 1.938B |
| Corcept Therapeutics, Inc. | 13.00B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.898M |
| Revenue (Quarterly) | 20.73M |
| Total Expenses (Quarterly) | 26.63M |
| EPS Diluted (Quarterly) | -0.1142 |
| Gross Profit Margin (Quarterly) | 93.04% |
| Profit Margin (Quarterly) | -28.45% |
| Earnings Yield | 5.93% |
| Operating Earnings Yield | 0.25% |
| Normalized Earnings Yield | 7.032 |